Company: MIRA
Filing Date: 2025-07-29
Form Type: PRER14A
Source: 0001641172-25-021434
Chunk: 67

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-07-29
Form: PRER14A
Chunk 67
---
 the MIRA, and to cause such shares to be approved for listing (subject to official notice of issuance), and (iii) to the extent required by Nasdaq Marketplace Rule 5110, to file an initial Nasdaq Listing Application for the MIRA Common Stock on Nasdaq and to cause such listing application to be conditionally approved prior to the Effective Time.

In addition, under the Merger Agreement, each of SKNY’s and MIRA’s obligation to complete the Merger is subject to the satisfaction or waiver by each of the parties, at or prior to the Closing, of various conditions, including that the shares of MIRA Common Stock to be issued in the Merger have been approved for listing (subject to official notice of issuance) on Nasdaq as of the Closing.

<div align='center'>THE MERGER AGREEMENT</div>

The following is a summary of the material terms of the Merger Agreement. A copy of the Merger Agreement is attached as Annex A to this proxy statement and is incorporated by reference. The Merger Agreement has been attached to this proxy statement to provide you with information regarding its terms. It is not intended to provide any other factual information about MIRA, SKNY or Merger Sub. The following description does not purport to be complete and is qualified in its entirety by reference to the Merger Agreement. You should refer to the full text of the Merger Agreement for details of the Merger and the terms and conditions of the Merger Agreement.

Parties to the Merger

The Agreement and Plan of Merger, dated June 16, 2025 (“Merger Agreement”), is entered into by and among MIRA Pharmaceuticals, Inc., a Florida corporation, MIRAPHARM Acquisition, Inc., a Delaware corporation and a wholly owned subsidiary of MIRA (“Merger Sub”), and SKNY. Merger Sub will merge with and into SKNY, with SKNY being the surviving corporation (the “Merger”).

Form of the Merger

Pursuant to the Merger Agreement, subject to the terms and conditions set forth therein upon the consummation of the transactions contemplated by the Merger Agreement, Merger Sub will merge with and into SKNY, with SKNY continuing as the surviving corporation in the Merger and a wholly-owned subsidiary of MIRA. In the Merger, all of the issued and outstanding SKNY Shares immediately prior to the Effective Time shall no longer be outstanding and shall be exchanged for and automatically converted into that certain number of fully paid and non